Works matching AU Kapiteijn, E.

Results: 25

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Published in:

British Journal of Cancer, 2025, v. 132, n. 12, p. 1124, doi. 10.1038/s41416-025-03021-5

By:

Bloem, M.;
de Meza, M. M.;
van den Eertwegh, A. J. M.;
Aarts, M. J. B.;
van den Berkmortel, F. W. P. J.;
Blank, C. U.;
Blokx, W. A. M.;
Boers-Sonderen, M. J.;
Bonenkamp, J. J.;
Boreel, C. D. M.;
de Groot, J. W. B.;
Haanen, J. B. A. G.;
Hospers, G. A. P.;
Kapiteijn, E.;
van Not, O. J.;
Piersma, D.;
Rikhof, B.;
Stevense-den Boer, A. M.;
van der Veldt, A. A. M.;
Vreugdenhil, G.

Publication type:

Article

Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.

Published in:

Acta Oncologica, 2021, v. 60, n. 1, p. 69, doi. 10.1080/0284186X.2020.1818823

By:

Boekhout, A. H.;
Rogiers, A.;
Jozwiak, K.;
Boers-Sonderen, M. J.;
van den Eertwegh, A. J.;
Hospers, G. A.;
de Groot, J. W. B.;
Aarts, M. J. B.;
Kapiteijn, E.;
ten Tije, A. J.;
Piersma, D.;
Vreugdenhil, G.;
van der Veldt, A. A.;
Suijkerbuijk, K. P. M.;
Rozeman, E. A.;
Neyns, B.;
Janssen, K. J.;
van de Poll-Franse, L. V.;
Blank, C. U.

Publication type:

Article

Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.

Published in:

Acta Oncologica, 2017, v. 56, n. 1, p. 101, doi. 10.1080/0284186X.2016.1260773

By:

van der Kooij, M. K.;
Joosse, A.;
Speetjens, F. M.;
Kapiteijn, E.;
Hospers, G. A. P.;
Bisschop, C.;
de Groot, J. W. B.;
Koornstra, R.;
Blank, C. U.

Publication type:

Article

Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data.

Published in:

European Journal of Endocrinology, 2020, v. 182, n. 2, p. 131, doi. 10.1530/eje-19-0763

By:

Aydemirli, M. D.;
Kapiteijn, E.;
Ferrier, K. R. M.;
Ottevanger, P. B.;
Links, T. P.;
van der Horst-Schrivers, A. N. A.;
Broekman, K. E.;
Groenwold, R. H. H.;
Zwaveling, J.

Publication type:

Article

Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma.

Published in:

European Journal of Endocrinology, 2019, v. 180, n. 4, p. 235, doi. 10.1530/EJE-18-0653

By:

van der Tuin, K.;
Garcia, M. Ventayol;
Corver, W. E.;
Khalifa, M. N.;
RuanoNeto, D.;
Corssmit, E. P. M.;
Hes, F. J.;
Links, T. P.;
Smit, J. W. A.;
Plantinga, T. S.;
Kapiteijn, E.;
van Wezel, T.;
Morreau, H.

Publication type:

Article

Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.

Published in:

European Journal of Endocrinology, 2015, v. 172, n. 5, p. R215, doi. 10.1530/EJE-14-0788

By:

Hesselink, E. N. Klein;
Steenvoorden, D.;
Kapiteijn, E.;
Corssmit, E. P.;
van der Horst-Schrivers, A. N. A.;
Lefrandt, J. D.;
Links, T. P.;
Dekkers, O. M.

Publication type:

Article

Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.

Published in:

European Journal of Endocrinology, 2012, v. 167, n. 5, p. 643, doi. 10.1530/EJE-12-0405

By:

Schneider, T. C.;
Abdulrahman, R. M.;
Corssmit, E. P.;
Morreau, H;
Smit, J. W. A.;
Kapiteijn, E.

Publication type:

Article

Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer.

Published in:

2016

By:

Wit, D.;
Schneider, T.;
Moes, D.;
Roozen, C.;
Hartigh, J.;
Gelderblom, H.;
Guchelaar, H.;
Hoeven, J.;
Links, T.;
Kapiteijn, E.;
Erp, N.;
de Wit, D;
Schneider, T C;
Moes, D J A R;
Roozen, C F M;
den Hartigh, J;
Guchelaar, H J;
van der Hoeven, J J;
Links, T P;
van Erp, N P

Publication type:

journal article

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.

Published in:

International Journal of Clinical Oncology, 2018, v. 23, n. 3, p. 482, doi. 10.1007/s10147-017-1220-0

By:

Kwakman, Johannes J. M.;
Vink, G.;
Vestjens, J. H.;
Beerepoot, L. V.;
de Groot, J. W.;
Jansen, R. L.;
Opdam, F. L.;
Boot, H.;
Creemers, G. J.;
van Rooijen, J. M.;
Los, M.;
Vulink, A. J. E.;
Schut, H.;
van Meerten, E.;
Baars, A.;
Hamberg, P.;
Kapiteijn, E.;
Sommeijer, D. W.;
Punt, C. J. A.;
Koopman, M.

Publication type:

Article

Correction to: Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases.

Published in:

2024

By:

Tong, T. M. L.;
Fiocco, M.;
van Duijn-de Vreugd, J. J.;
Lutjeboer, J.;
Speetjens, F. M.;
Tijl, F. G. J.;
Sitsen, M. E.;
Zoethout, R. W. M.;
Martini, C. H.;
Vahrmeijer, A. L.;
van der Meer, R. W.;
van Rijswijk, C. S. P.;
van Erkel, A. R.;
Kapiteijn, E.;
Burgmans, M. C.

Publication type:

Correction Notice

Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases.

Published in:

CardioVascular & Interventional Radiology, 2024, v. 47, n. 6, p. 741, doi. 10.1007/s00270-024-03713-0

By:

Tong, T. M. L.;
Fiocco, M.;
van Duijn-de Vreugd, J. J.;
Lutjeboer, J.;
Speetjens, F. M.;
Tijl, F. G. J.;
Sitsen, M. E.;
Zoethout, R. W. M.;
Martini, C. H.;
Vahrmeijer, A. L.;
van der Meer, R. W.;
van Rijswijk, C. S. P.;
van Erkel, A. R.;
Kapiteijn, E.;
Burgmans, M. C.

Publication type:

Article

Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.

Published in:

CardioVascular & Interventional Radiology, 2023, v. 46, n. 3, p. 350, doi. 10.1007/s00270-022-03338-1

By:

Tong, T. M. L.;
Burgmans, M. C.;
Speetjens, F. M.;
van Erkel, A. R.;
van der Meer, R. W.;
van Rijswijk, C. S. P.;
Jonker-Bos, M. A.;
Roozen, C. F. M.;
Sporrel-Blokland, M.;
Lutjeboer, J.;
van Persijn van Meerten, E. L.;
Martini, C. H.;
Zoethout, R. W. M.;
Tijl, F. G. J.;
Blank, C. U.;
Kapiteijn, E.

Publication type:

Article

Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.

Published in:

2022

By:

Tong, T. M. L.;
Samim, M.;
Kapiteijn, E.;
Meijer, T. S.;
Speetjens, F. M.;
Brüning, R.;
Schroeder, T. H.;
El-Sanosy, S.;
Maschke, H.;
Wacker, F. K.;
Vogel, A.;
Dewald, C. L. A.;
Goeman, J. J.;
Burgmans, M. C.

Publication type:

journal article

Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.

Published in:

2016

By:

Schneider, T C;
de Wit, D;
Links, T P;
van Erp, N P;
van der Hoeven, J J M;
Gelderblom, H;
Roozen, C F M;
Bos, M;
Corver, W E;
van Wezel, T;
Smit, J W A;
Morreau, H;
Guchelaar, H J;
Kapiteijn, E;
Schneider, Tatiana C;
de Wit, Djoeke;
Links, Thera P;
van Erp, Nielka P;
van der Hoeven, Jakobus J M;
Gelderblom, Hans

Publication type:

journal article

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol.

Published in:

BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12336-0

By:

Janssen, J. C.;
van Dijk, B.;
de Joode, K.;
Aarts, M. J. B.;
van den Berkmortel, F. W. P. J.;
Blank, C. U.;
Boers-Sonderen, M. J.;
van den Eertwegh, A. J. M.;
de Groot, J. W. B.;
Jalving, M.;
de Jonge, M. J. A.;
Joosse, A.;
Kapiteijn, E.;
Kamphuis-Huismans, A. M.;
Naipal, K. A. T.;
Piersma, D.;
Rikhof, B.;
Westgeest, H. M.;
Vreugdenhil, G.;
Oomen-de Hoop, E.

Publication type:

Article

Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort.

Published in:

Pigment Cell & Melanoma Research, 2024, v. 37, n. 1, p. 15, doi. 10.1111/pcmr.13117

By:

Borgers, J. S. W.;
Burgers, F. H.;
Schina, A.;
Van Not, O. J.;
van den Eertwegh, A. J. M.;
Blank, C. U.;
Aarts, M. J. B.;
van den Berkmortel, F. W. P. J.;
de Groot, J. W. B.;
Hospers, G. A. P.;
Kapiteijn, E.;
Piersma, D.;
van Rijn, R. S.;
Boer, A. M. Stevense‐den;
van der Veldt, A. A. M.;
Vreugdenhil, G.;
Boers‐Sonderen, M. J.;
Wouters, M. W. J. M.;
Suijkerbuijk, K. P. M.;
van Thienen, J. V.

Publication type:

Article

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.

Published in:

2021

By:

Mulder, E. E. A. P.;
de Joode, K.;
Litière, S.;
ten Tije, A. J.;
Suijkerbuijk, K. P. M.;
Boers-Sonderen, M. J.;
Hospers, G. A. P.;
de Groot, J. W. B.;
van den Eertwegh, A. J. M.;
Aarts, M. J. B.;
Piersma, D.;
van Rijn, R. S.;
Kapiteijn, E.;
Vreugdenhil, G.;
van den Berkmortel, F. W. P. J.;
Hoop, E. Oomen-de;
Franken, M. G.;
Ryll, B.;
Rutkowski, P.;
Sleijfer, S.

Publication type:

journal article

A unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literature.

Published in:

Familial Cancer, 2020, v. 19, n. 1, p. 15, doi. 10.1007/s10689-019-00146-4

By:

Aydemirli, M. D.;
van der Tuin, K.;
Hes, F. J.;
van den Ouweland, A. M. W.;
van Wezel, T.;
Kapiteijn, E.;
Morreau, H.

Publication type:

Article

Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

Published in:

Quality of Life Research, 2023, v. 32, n. 9, p. 2517, doi. 10.1007/s11136-023-03427-9

By:

Egeler, M. D.;
van de Poll-Franse, L. V.;
Tissier, R.;
Rogiers, A.;
Boers-Sonderen, M. J.;
van den Eertwegh, A. J.;
Hospers, G. A.;
de Groot, J. W. B.;
Aarts, M. J. B.;
Kapiteijn, E.;
Piersma, D.;
Vreugdenhil, G.;
van der Veldt, A. A.;
Suijkerbuijk, K. P. M.;
Neyns, B.;
Janssen, K. J.;
Blank, C. U.;
Retèl, V. P.;
Boekhout, A. H.

Publication type:

Article

Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.

Published in:

2022

By:

Tong, T. M. L.;
van der Kooij, M. K.;
Speetjens, F. M.;
van Erkel, A. R.;
van der Meer, R. W.;
Lutjeboer, J.;
van Persijn van Meerten, E. L.;
Martini, C. H.;
Zoethout, R. W. M.;
Tijl, F. G. J.;
Blank, C. U.;
Burgmans, M. C.;
Kapiteijn, E.

Publication type:

journal article

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.

Published in:

British Journal of Cancer, 2023, v. 128, n. 6, p. 1040, doi. 10.1038/s41416-022-02133-6

By:

Piperno-Neumann, S.;
Carlino, M. S.;
Boni, V.;
Loirat, D.;
Speetjens, F. M.;
Park, J. J.;
Calvo, E.;
Carvajal, R. D.;
Nyakas, M.;
Gonzalez-Maffe, J.;
Zhu, X.;
Shirley, M. D.;
Ramkumar, T.;
Fessehatsion, A.;
Burks, H. E.;
Yerramilli-Rao, P.;
Kapiteijn, E.

Publication type:

Article

Managing rectal cancer: the Dutch experience.

Published in:

Colorectal Disease, 2003, v. 5, n. 5, p. 423, doi. 10.1046/j.1463-1318.2003.00513.x

By:

Peeters, K. C. M. J.;
Kapiteijn, E.;
van de Velde, C. J. H.

Publication type:

Article

Mechanisms of oncogenesis in colon versus rectal cancer.

Published in:

Journal of Pathology, 2001, v. 195, n. 2, p. 171, doi. 10.1002/path.918

By:

Kapiteijn, E.;
Liefers, G. J.;
Los, L. C.;
Klein Kranenbarg, E.;
Hermans, J.;
Tollenaar, R. A. E. M.;
Moriya, Y.;
van de Velde, C. J. H.;
van Krieken, J. H. J. M.

Publication type:

Article

Survival of stage IV melanoma in Belgium and the Netherlands.

Published in:

Journal of the European Academy of Dermatology & Venereology, 2022, v. 36, n. 2, p. e118, doi. 10.1111/jdv.17668

By:

Suijkerbuijk, K.P.M.;
Haanen, J.B.A.G.;
Boers‐Sonderen, M.J.;
Hospers, G.A.P.;
Blank, C.U.;
van den Berkmortel, F.W.P.J.;
de Groot, J.W.B.;
Piersma, D.;
Aarts, M.J.B.;
van Rijn, R.S.;
Vreugdenhil, G.;
Westgeest, H.M.;
Kapiteijn, E.;
van der Veldt, A.A.M.;
van den Eertwegh, A.J.M.

Publication type:

Article

Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands.

Published in:

British Journal of Surgery, 2002, v. 89, n. 9, p. 1142, doi. 10.1046/j.1365-2168.2002.02196.x

By:

Kapiteijn, E.;
Putter, H.;
van de Velde, C. J. H.

Publication type:

Article